500 Boylston Street
37 articles with Vedanta Biosciences
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history of peanut allergy
Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that a Vedanta scientific team member, Silvia Caballero, Ph.D., has been named as one of MIT Technology Review’s Global Innovators Under 35.
Vedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease Week
Vedanta Biosciences, today announced the presentation of expanded, long-term positive data from its Phase 1a/1b study of VE303, the Company’s lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI).
PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week
PureTech Health plc announced that its affiliates Gelesis and Vedanta Biosciences will deliver poster presentations of clinical data at Digestive Disease Week, the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
$18.5 million in extension funding will support clinical pipeline of microbiome-derived product candidates
Upheld patent EP2575835 covers therapeutic compositions of clostridial bacterial species derived from the human microbiome
Vedanta Biosciences Announces Publication in Nature of Seminal Research Revealing A New Mechanism of Human Microbiota-Driven Antitumor Immunity Involving Induction of IFNy+ CD8+ T Cell Accumulation in the Gut and Tumors
Research also identified a rationally-defined consortium of human commensal bacteria (VE800) that robustly induces IFNy+ CD8+ T cells and enhances antitumor immunity
Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates
Participants include the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure, and PureTech Health
Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303
First drug consisting of a rationally-defined bacterial consortium to advance to Phase 2 study
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
Bristol-Myers Squibb Company and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
Bristol-Myers Squibb Company and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.
Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease
First clinical study of a rationally-defined bacterial consortium for an immune-mediated disease
VE800 shown to induce cytotoxic T cells and a systemic immune response both as a monotherapy and in combination with checkpoint inhibitors
Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
All doses were safe and well-tolerated
Former Global Head of Immunology at Janssen led development of multiple innovative therapies
Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease
Company also announces research collaboration with Keio University School of Medicine for this new IBD program
Vedanta Biosciences announced that Chief Executive Officer, Bernat Olle, Ph.D., will present at the Jefferies 2018 Global Healthcare Conference.
Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
The newly issued patents are exclusively licensed to Vedanta under an agreement with the University of Tokyo and provide coverage through at least 2031.
Vedanta Biosciences Announces Initiation of Phase 1a/1b Trial for New Drug Class of Rationally-Defined Bacterial Consortia Derived from the Human Microbiome
VE303 is an orally-administered investigational microbiome therapeutic consisting of live bacteria designed to restore colonization resistance against gut pathogens, including C. difficile, following recurrence.